Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...
Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...
The Associated Press on MSN13d
A spine-zapping implant helped 3 people with a muscle-wasting disease walk betterThree people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...
In a groundbreaking pilot study, researchers have found evidence that spinal cord stimulation could potentially benefit ...
In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.
Nerve cells in the spinal cord do not regenerate easily and scar tissue forms quickly ... and improving recovery. Shortly after the injury, steroid medications and surgery are used to help reduce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback